Try our mobile app

Switch to company model in classical logic    *

General information

Country: UNITED STATES

Sector: Medical Devices

TransMedics Group, Inc. is a commercial stage medical technology company, which engages in the development and commercialization of organ care system platform. The company is headquartered in Andover, Massachusetts and currently employs 92 full-time employees. The company is focused on developing organ transplant therapy for end-stage organ failure patients across multiple disease states. The firm has designed and developed organ care system (OCS) a portable organ perfusion, optimization and monitoring system that utilizes customized technology to replicate near-physiologic conditions for donor organs outside of the human body. The company has developed three OCS products, one for each of lung, heart and liver transplantations. Its OCS clinical programs include OCS Lung INSPIRE Trial, OCS Lung Expand Trial, OCs Heart EXPAND and PROCEED II Trials. Its organ care system (OCS) technology platform to perfuse donor organs with warm, oxygenated, nutrient-enriched blood, while maintaining the organs in a living, functioning state; the lung is breathing, the heart is beating and the liver is producing bile. The company is also focused on developing additional OCS products for kidney transplantation.
Website: transmedics.com



Growth: Good revenue growth rate 32.1%, there is slowdown compared to average historical growth rates 109.1%. The revenue growth dynamics is stable

Profitability: LTM EBITDA margin is positive, +21.9%. On average the margin is improving unsteadily. Gross margin is high, +58.8%. In the last quarter the company beat the estimated EPS. The company was ahead of estimated EPS in 80% of quarters (showing a gain of +$0.07 per share on average)

Cash Flow Generation: Dividend yield for the last twelve months 0.0%. Free cash flow yield 2.8% (LTM)

Undervaluation: Fundamental value created in LTM (estimate)


Entry Point: Share price is 279.2% higher than minimum and 20.9% lower than maximum for the last 3 years

AI Insight: the companies with similar growth trajectories, EBITDA margin, industries and geography on average are valued 7.0x by EV / Sales multiple , the company can be 16.9% overvalued

Insiders: For the last 3 months insiders sold company shares on $0.3 mln (0.000% of cap.)

Key Financials (Download financials)

Ticker: TMDX
Share price, USD:  (0.0%)139.33
year average price 113.63  


year start price 71.22 2025-02-13

min close price 64.35 2025-03-13

max close price 150.42 2025-12-01

current price 139.33 2026-02-13
Common stocks: 34 112 452

Dividend Yield:  0.0%
FCF Yield LTM: 2.8%
EV / LTM EBITDA: 38.8x
EV / EBITDA annualized: 40.0x
Last revenue growth (y/y):  +32.1%
Last growth of EBITDA (y/y):  +100.0%
Historical revenue growth:  +109.1%
Historical growth of EBITDA:  +125.0%
EV / Sales: 8.5x
Margin (EBITDA LTM / Revenue): 21.9%
Fundamental value created in LTM:
Market Cap ($m): 4 753
Net Debt ($m): 53
EV (Enterprise Value): 4 806
Price to Book: 13.4x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / Sales

Potential dynamics

News


2026-02-03seekingalpha.com

TransMedics: Italian NOP Program Reinforces Huge International Opportunity

2026-01-14zacks.com

Reasons to Retain TransMedics Stock in Your Portfolio for Now

2026-01-13seekingalpha.com

TransMedics Group, Inc. (TMDX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

2026-01-12prnewswire.com

TransMedics Announces New Global Headquarters and Expansion at Assembly Innovation Park in Somerville, Massachusetts

2025-12-24prnewswire.com

TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

2025-12-24seekingalpha.com

TransMedics Group: I Estimate A Large Upside By The End Of 2028

2025-10-30zacks.com

TMDX Stock Falls Despite Q3 Earnings Beat Estimates, Revenues Up Y/Y

2025-10-29seekingalpha.com

TransMedics Group, Inc. (TMDX) Q3 2025 Earnings Call Transcript

2025-10-29zacks.com

TransMedics (TMDX) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates

2025-10-29zacks.com

TransMedics (TMDX) Beats Q3 Earnings Estimates
More information for subscribed users:
detailed calculation of
Fundamental value created in LTM

Financial reporting

Income Statement

Property 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4
date 2025-09-30 2025-06-30 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-12-31 2020-12-31
symbol TMDX TMDX TMDX TMDX TMDX TMDX TMDX TMDX TMDX TMDX TMDX TMDX TMDX TMDX
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M
fillingDate 2025-10-29 2025-07-30 2024-10-29 2024-08-01 2024-05-02 2023-11-08 2023-08-04 2023-05-04 2022-11-04
acceptedDate 2025-10-29 16:23:21 2025-07-30 16:29:15 2025-02-27 16:26:52 2024-10-29 16:22:39 2024-08-01 16:19:35 2024-05-02 16:27:33 2024-02-27 16:15:09 2023-11-08 16:47:51 2023-08-04 16:36:53 2023-05-04 16:21:57 2023-02-27 16:17:00 2022-11-04 16:16:22 2022-03-01 16:16:41 2021-03-11 16:19:02
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2022
period Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 FY FY
revenue 144M 157M 442M 109M 114M 97M 242M 66M 52M 42M 93M 26M 30M 26M
costOfRevenue 59M 61M 179M 48M 45M 37M 88M 26M 16M 13M 28M 8M 9M 9M
grossProfit 85M 97M 262M 61M 69M 60M 154M 41M 37M 29M 65M 18M 21M 17M
grossProfitRatio 0.588 0.614 0.559 0.605 0.618 0.612 0.7 0.692 0.705
researchAndDevelopmentExpenses 15M 16M 56M 14M 14M 11M 63M 38M 8M 6M 27M 7M 22M 19M
generalAndAdministrativeExpenses 45M 44M 169M 0 43M 36M 120M 31M 28M 25M 52M 17M 38M 24M
sellingAndMarketingExpenses 1M 0 0 0 -100 000 -100 000 0 0 1M 0 18M 0 0 0
sellingGeneralAndAdministrativeExpenses 46M 44M 169M 43M 43M 36M 120M 31M 29M 25M 70M 17M 38M 24M
otherExpenses 0 0 0 0 0 4M 0 5M 2M 555 000 0 0 0 0
operatingExpenses 61M 60M 225M 57M 57M 47M 183M 69M 38M 31M 97M 24M 61M 43M
costAndExpenses 121M 121M 404M 105M 102M 84M 270M 95M 53M 44M 125M 31M 70M 52M
interestIncome 0 3M 0 0 3M 4M 13M 5M 2M 0 900 000 0 0 2M
interestExpense 3M 3M 14M 0 4M 4M 11M 4M 3M 1M 4M 787 000 4M 4M
depreciationAndAmortization 7M 7M 20M 9M 5M 4M 8M 5M 2M 555 000 3M -185 000 2M 2M
ebitda 33M 46M 70M 13M 17M 17M -8M -23M 2M -2M -29M -6M -38M -23M
ebitdaratio 0.232 0.295 0.12 0.15 0.174 -0.351 0.029 -0.037 -0.223
operatingIncome 23M 37M 37M 4M 13M 12M -29M -28M -906 000 -2M -31M -6M -39M -26M
operatingIncomeRatio 0.162 0.232 0.036 0.109 0.128 -0.427 -0.017 -0.05 -0.216
totalOtherIncomeExpensesNet -269 000 -385 000 -2M 322 000 -355 000 -28 000 2M 5M 2M -536 000 -5M -2M -5M -2M
incomeBeforeTax 23M 36M 36M 4M 12M 12M -27M -27M -980 000 -3M -36M -7M -44M -29M
incomeBeforeTaxRatio 0.16 0.23 0.039 0.106 0.128 -0.405 -0.019 -0.063 -0.288
incomeTaxExpense -1M 1M 316 000 29 000 -41 000 196 000 -2M -2M 21 000 11 000 66 000 19 000 36 000 32 000
netIncome 24M 35M 35M 4M 12M 12M -25M -25M -1M -3M -36M -7M -44M -29M
netIncomeRatio 0.169 0.222 0.039 0.107 0.126 -0.383 -0.019 -0.063 -0.289
eps 0.71 1.03 1.07 0.13 0.37 0.37 -0.77 -0.78 -0.031 -0.082 -1.23 -0.25 -1.6 -1.16
epsdiluted 0.66 0.92 0.12 0.35 0.35 -0.78 -0.031 -0.082 -0.25
weightedAverageShsOut 34M 34M 33M 33M 33M 33M 33M 33M 33M 32M 30M 30M 28M 25M
weightedAverageShsOutDil 41M 41M 35M 36M 35M 35M 33M 33M 33M 32M 30M 30M 28M 25M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link
filingDate 2025-02-27 2024-02-27 2023-02-27 2022-03-01 2021-03-11
fiscalYear 2024 2023 2022 2021 2020
netInterestIncome -14M 2M -3M -4M -2M
ebit 50M -16M -32M -40M -25M
nonOperatingIncomeExcludingInterest -13M -13M 1M 877 000 -2M
netIncomeFromContinuingOperations 35M -25M -36M -44M -29M
netIncomeFromDiscontinuedOperations 0 0 0 0 0
otherAdjustmentsToNetIncome 0 0 0 0 0
netIncomeDeductions 0 0 0 0 0
bottomLineNetIncome 35M -25M -36M -44M -29M
epsDiluted 1.01 -0.77 -1.23 -1.6 -1.16

Balance Sheet Statement

Property 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4
date 2025-09-30 2025-06-30 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-12-31 2020-12-31
symbol TMDX TMDX TMDX TMDX TMDX TMDX TMDX TMDX TMDX TMDX TMDX TMDX TMDX TMDX
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M
fillingDate 2025-10-29 2025-07-30 2024-10-29 2024-08-01 2024-05-02 2023-11-08 2023-08-04 2023-05-04 2022-11-04
acceptedDate 2025-10-29 16:23:21 2025-07-30 16:29:15 2025-02-27 16:26:52 2024-10-29 16:22:39 2024-08-01 16:19:35 2024-05-02 16:27:33 2024-02-27 16:15:09 2023-11-08 16:47:51 2023-08-04 16:36:53 2023-05-04 16:21:57 2023-02-27 16:17:00 2022-11-04 16:16:22 2022-03-01 16:16:41 2021-03-11 16:19:02
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2022
period Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 FY FY
cashAndCashEquivalents 466M 401M 337M 330M 363M 350M 395M 427M 582M 195M 201M 204M 26M 25M
shortTermInvestments 0 0 0 0 0 0 0 0 0 0 0 0 67M 101M
cashAndShortTermInvestments 466M 401M 337M 330M 363M 350M 395M 427M 582M 195M 201M 204M 92M 126M
netReceivables 81M 105M 98M 90M 81M 82M 64M 61M 48M 39M 28M 22M 6M 7M
inventory 45M 39M 47M 52M 49M 49M 44M 39M 31M 24M 21M 19M 15M 12M
otherCurrentAssets 22M 14M 16M 20M 17M 8M 8M 10M 2M 4M 3M 6M 5M 2M
totalCurrentAssets 613M 558M 497M 492M 509M 488M 511M 537M 663M 262M 252M 251M 119M 147M
propertyPlantEquipmentNet 319M 318M 292M 279M 235M 221M 180M 138M 27M 24M 24M 24M 16M 5M
goodwill 12M 12M 12M 12M 12M 12M 12M 12M 0 0 0 0 0 0
intangibleAssets 2M 2M 2M 2M 2M 2M 2M 2M 0 0 0 0 0 0
goodwillAndIntangibleAssets 14M 14M 14M 14M 14M 14M 14M 14M 0 0 0 0 0 0
longTermInvestments 0 0 0 0 500 000 500 000 0 500 000 750 000 0 500 000 0 500 000 0
taxAssets 0 0 0 0 0 0 0 -500 000 0 0 0 0 0 0
otherNonCurrentAssets 726 000 721 000 708 000 663 000 84 000 85 000 562 000 560 000 59 000 1M 0 500 000 0 506 000
totalNonCurrentAssets 333M 332M 307M 293M 249M 236M 195M 153M 28M 25M 25M 24M 16M 5M
otherAssets 0 0 0 0 0 0 0 0 0 0 0 0 0 0
totalAssets 946M 891M 804M 786M 759M 724M 706M 689M 690M 287M 277M 275M 135M 152M
accountPayables 12M 10M 10M 13M 13M 9M 13M 13M 7M 4M 3M 3M 7M 1M
shortTermDebt 8M 3M 3M 5M 4M 2M 0 2M 2M 1M 0 1M 0 0
taxPayables 0 0 0 0 0 0 0 0 0 0 0 0 0 0
deferredRevenue 3M 2M 2M 2M 1M 2M 2M 3M 244 000 244 000 241 000 226 000 250 000 263 000
otherCurrentLiabilities 56M 42M 45M 40M 36M 37M 18M 32M 23M 23M 9M 16M 11M 6M
totalCurrentLiabilities 80M 57M 60M 60M 54M 50M 55M 49M 32M 29M 24M 21M 23M 12M
longTermDebt 511M 516M 509M 516M 514M 507M 506M 514M 513M 66M 59M 66M 35M 35M
deferredRevenueNonCurrent 0 0 0 0 0 0 0 0 0 0 0 0 0 0
deferredTaxLiabilitiesNonCurrent 0 0 0 0 0 0 0 0 0 0 0 0 0 0
otherNonCurrentLiabilities 0 0 0 0 0 7M 0 0 0 0 0 62M 0 2M
totalNonCurrentLiabilities 511M 516M 516M 516M 514M 514M 514M 514M 513M 66M 66M 66M 44M 36M
otherLiabilities 0 0 0 0 0 0 0 0 0 0 0 0 0 0
capitalLeaseObligations 8M 8M 6M 10M 9M 7M 10M 10M 10M 9M 9M 9M 9M 0
totalLiabilities 591M 572M 575M 576M 569M 564M 569M 563M 545M 94M 90M 87M 67M 48M
preferredStock 0 0 0 0 0 0 0 0 0 0 0 0 0 0
commonStock 738M 726M 697M 685M 669M 651M 641M 634M 628M 674M 666M 660M 510M 502M
retainedEarnings -383M -408M -468M -475M -479M -492M -504M -508M -482M -481M -479M -472M -442M -398M
accumulatedOtherComprehensiveIncomeLoss 101 000 98 000 -364 000 -233 000 -237 000 -182 000 -199 000 -262 000 -220 000 -218 000 -225 000 -247 000 -188 000 -95 000
othertotalStockholdersEquity 0 0 0 0 0 0 0 0 0
totalStockholdersEquity 355M 318M 229M 210M 190M 159M 137M 126M 145M 193M 187M 188M 68M 104M
totalEquity 355M 318M 229M 210M 190M 159M 137M 126M 145M 193M 187M 188M 68M 104M
totalLiabilitiesAndStockholdersEquity 946M 891M 786M 759M 724M 689M 690M 287M 275M
minorityInterest 0 0 0 0 0 0 0 0 0 0 0 0 0 0
totalLiabilitiesAndTotalEquity 946M 891M 804M 786M 759M 724M 706M 689M 690M 287M 277M 275M 135M 152M
totalInvestments 0 0 0 500 000 500 000 500 000 0 500 000 750 000 0 500 000 0 67M 101M
totalDebt 519M 519M 518M 518M 516M 516M 516M 516M 515M 67M 68M 68M 44M 35M
netDebt 53M 118M 182M 188M 154M 166M 121M 89M -67M -128M -134M -137M 18M 10M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link
filingDate 2025-02-27 2024-02-27 2023-02-27 2022-03-01 2021-03-11
fiscalYear 2024 2023 2022 2021 2020
accountsReceivables 98M 64M 28M 6M 7M
otherReceivables 0 0 0 0 0
prepaids 0 0 0 0 0
totalPayables 10M 13M 3M 7M 1M
otherPayables 0 0 0 0 0
accruedExpenses 0 20M 10M 5M 4M
capitalLeaseObligationsCurrent 0 2M 1M 0 0
capitalLeaseObligationsNonCurrent 6M 8M 7M 9M 0
treasuryStock 0 0 0 0 0
additionalPaidInCapital 0 0 0 0 0
otherTotalStockholdersEquity 0 0 0 0 0

Cash Flow Statement

Property 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4
date 2025-09-30 2025-06-30 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-12-31 2020-12-31
symbol TMDX TMDX TMDX TMDX TMDX TMDX TMDX TMDX TMDX TMDX TMDX TMDX TMDX TMDX
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M
fillingDate 2025-10-29 2025-07-30 2024-10-29 2024-08-01 2024-05-02 2023-11-08 2023-08-04 2023-05-04 2022-11-04
acceptedDate 2025-10-29 16:23:21 2025-07-30 16:29:15 2025-02-27 16:26:52 2024-10-29 16:22:39 2024-08-01 16:19:35 2024-05-02 16:27:33 2024-02-27 16:15:09 2023-11-08 16:47:51 2023-08-04 16:36:53 2023-05-04 16:21:57 2023-02-27 16:17:00 2022-11-04 16:16:22 2022-03-01 16:16:41 2021-03-11 16:19:02
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2022
period Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 FY FY
netIncome 24M 35M 35M 4M 12M 12M -25M -25M -1M -3M -36M -7M -44M -29M
depreciationAndAmortization 7M 7M 20M 5M 5M 4M 8M 2M 1M 1M 3M 891 000 2M 2M
deferredIncomeTax 0 0 0 0 0 0 -2M -1M -13 000 0 0 0 0 -431 000
stockBasedCompensation 9M 9M 33M 8M 8M 7M 20M 5M 5M 4M 10M 3M 7M 2M
changeInWorkingCapital 28M 40M -45M -11M 177 000 -28M -44M -16M -12M -11M -27M -12M 3M -6M
accountsReceivables 24M 38M -34M 0 757 000 -18M -34M -11M -9M -11M -22M -9M 840 000 -218 000
inventory -7M 4M -8M 0 -2M -6M -28M -10M -7M -4M -8M -2M -5M -2M
accountsPayables 2M -1M -1M -36 000 4M -2M 7M 3M 3M 1M -3M -2M 5M -6M
otherWorkingCapital 8M 144 000 -941 000 -11M -2M -2M 11M 3M 2M 2M 6M 961 000 2M 2M
otherNonCashItems 1M 414 000 5M 769 000 16M 43M 30M 28M 719 000 160 000 3M 2M 4M 511 000
netCashProvidedByOperatingActivities 70M 92M 49M 7M 26M -3M -13M -7M -6M -9M -46M -14M -29M -30M
investmentsInPropertyPlantAndEquipment -8M -9M 0 -48M -24M -44M -152M -135M -1M -927 000 -12M -3M -4M -455 000
acquisitionsNet 0 0 441 000 0 0 0 -15M -15M 0 0 107 000 0 0 41M
purchasesOfInvestments 0 0 0 0 0 0 0 0 0 0 -10M -988 000 -72M -122M
salesMaturitiesOfInvestments 0 0 0 0 0 0 0 0 0 0 77M 29M 105M 81M
otherInvestingActivites 0 0 441 000 0 0 0 0 0 0
netCashUsedForInvestingActivites -8M -9M -48M -24M -44M -150M -1M -927 000 25M
debtRepayment 0 0 0 0 0 0 -393M 0 0
commonStockIssued 4M 7M -14M 11M 3M 2M 705 000 4M 0
commonStockRepurchased 0 0 0 1M 0 638 000 0 0 0 384 000 0 0 0 0
dividendsPaid 0 0 0 0 0 0 0 0 0
otherFinancingActivites -138 000 0 8M 11M 3M 0 787M 0 164M
netCashUsedProvidedByFinancingActivities 4M 7M 8M 11M 3M 2M 394M 4M 164M
effectOfForexChangesOnCash 9000 809 000 -536 000 386 000 -62 000 -173 000 193 000 -177 000 5000 73 000 -1M -610 000 -797 000 803 000
netChangeInCash 66M 90M -58M -33M 13M -45M 194M -155M 387M -6M 176M 174M 999 000 4M
cashAtEndOfPeriod 466M 401M 337M 331M 363M 350M 395M 428M 583M 196M 202M 205M 26M 25M
cashAtBeginningOfPeriod 401M 311M 395M 363M 350M 395M 202M 583M 196M 202M 26M 31M 25M 21M
operatingCashFlow 70M 92M 49M 7M 26M -3M -13M -7M -6M -9M -46M -14M -29M -30M
capitalExpenditure -8M -9M -130M -48M -24M -44M -179M -135M -1M -927 000 -12M -3M -4M -455 000
freeCashFlow 62M 83M -81M -41M 2M -48M -192M -142M -7M -10M -58M -17M -32M -31M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link
filingDate 2025-02-27 2024-02-27 2023-02-27 2022-03-01 2021-03-11
fiscalYear 2024 2023 2022 2021 2020
otherInvestingActivities -130M -27M -107 000 0 -41M
netCashProvidedByInvestingActivities -129M -194M 55M 29M -42M
netDebtIssuance 0 445M 22M 0 0
longTermNetDebtIssuance 0 445M 22M 0 0
shortTermNetDebtIssuance 0 0 0 0 0
netStockIssuance 23M 0 140M 0 75M
netCommonStockIssuance 23M 0 140M 0 75M
commonStockIssuance 23M 0 140M 0 75M
netPreferredStockIssuance 0 0 0 0 0
netDividendsPaid 0 0 0 0 0
commonDividendsPaid 0 0 0 0 0
preferredDividendsPaid 0 0 0 0 0
otherFinancingActivities 0 -45M 6M 1M 584 000
netCashProvidedByFinancingActivities 23M 400M 168M 1M 76M
incomeTaxesPaid 0 0 0 0 0
interestPaid 0 8M 0 3M 0

Earning call transcript

2025 q3
2025-10-29 ET (fiscal 2025 q3)
2025 q2
2025-07-31 ET (fiscal 2025 q2)
2025 q1
2025-05-08 ET (fiscal 2025 q1)
2024 q4
2025-02-27 ET (fiscal 2024 q4)
2024 q3
2024-10-28 ET (fiscal 2024 q3)
2024 q2
2024-07-31 ET (fiscal 2024 q2)
2024 q1
2024-05-01 ET (fiscal 2024 q1)
2023 q4
2024-02-26 ET (fiscal 2023 q4)
2023 q3
2023-11-06 ET (fiscal 2023 q3)
2023 q2
2023-08-03 ET (fiscal 2023 q2)
2023 q1
2023-05-02 ET (fiscal 2023 q1)
2022 q4
2023-02-22 ET (fiscal 2022 q4)
2022 q3
2022-11-05 ET (fiscal 2022 q3)
2022 q2
2022-08-02 ET (fiscal 2022 q2)
2022 q1
2022-05-03 ET (fiscal 2022 q1)

SEC forms

Show financial reports only

SEC form 10
2025-10-29 20:23 ET
TransMedics Group reported for 2025 q3
SEC form 8
2025-10-29 20:11 ET
TransMedics Group published news for 2025 q3
SEC form 8
2025-10-29 20:11 ET
TransMedics Group published news for 2025 q3
SEC form 10
2025-07-30 20:29 ET
TransMedics Group reported for 2025 q2
SEC form 8
2025-07-30 20:09 ET
TransMedics Group published news for 2025 q2
SEC form 8
2025-07-30 20:09 ET
TransMedics Group published news for 2025 q2
SEC form 10
2025-05-08 20:15 ET
TransMedics Group reported for 2025 q1
SEC form 8
2025-05-08 20:05 ET
TransMedics Group published news for 2025 q1
SEC form 8
2025-05-08 20:05 ET
TransMedics Group published news for 2025 q1
SEC form 10
2025-05-08 00:00 ET
TransMedics Group published news for 2025 q1
SEC form 10
2025-02-27 16:26 ET
TransMedics Group reported for 2024 q4
SEC form 8
2025-02-27 16:15 ET
TransMedics Group published news for 2024 q4
SEC form 8
2025-02-27 16:15 ET
TransMedics Group published news for 2024 q4
SEC form 10
2025-02-27 00:00 ET
TransMedics Group published news for 2024 q4
SEC form 10
2024-10-29 16:22 ET
TransMedics Group reported for 2024 q3
SEC form 10
2024-10-29 00:00 ET
TransMedics Group published news for 2024 q3
SEC form 8
2024-10-28 16:11 ET
TransMedics Group published news for 2024 q3
SEC form 8
2024-10-28 16:11 ET
TransMedics Group published news for 2024 q3
SEC form 10
2024-08-01 16:19 ET
TransMedics Group published news for 2024 q2
SEC form 10
2024-08-01 00:00 ET
TransMedics Group published news for 2024 q2
SEC form 8
2024-07-31 17:09 ET
TransMedics Group reported for 2024 q2
SEC form 8
2024-07-31 17:09 ET
TransMedics Group published news for 2024 q2
SEC form 10
2024-05-02 00:00 ET
TransMedics Group published news for 2024 q1
SEC form 8
2024-04-30 16:31 ET
TransMedics Group reported for 2024 q1
SEC form 8
2024-04-30 16:31 ET
TransMedics Group published news for 2024 q1
SEC form 10
2024-02-27 16:15 ET
TransMedics Group published news for 2023 q4
SEC form 10
2024-02-27 00:00 ET
TransMedics Group published news for 2023 q4
SEC form 8
2024-02-26 16:19 ET
TransMedics Group published news for 2023 q4
SEC form 8
2024-02-26 16:19 ET
TransMedics Group reported for 2023 q4
SEC form 10
2023-11-08 00:00 ET
TransMedics Group published news for 2023 q3
SEC form 8
2023-11-06 16:23 ET
TransMedics Group reported for 2023 q3
SEC form 10
2023-08-04 16:36 ET
TransMedics Group published news for 2023 q2
SEC form 10
2023-08-04 00:00 ET
TransMedics Group published news for 2023 q2
SEC form 6
2023-08-03 16:29 ET
TransMedics Group reported for 2023 q2
SEC form 8
2023-08-03 00:00 ET
TransMedics Group published news for 2023 q2
SEC form 6
2023-06-29 16:05 ET
TransMedics Group published news for 2023 q1
SEC form 6
2023-06-07 16:30 ET
TransMedics Group published news for 2023 q1
SEC form 10
2023-05-04 00:00 ET
TransMedics Group published news for 2023 q1
SEC form 8
2023-05-01 00:00 ET
TransMedics Group published news for 2023 q1
SEC form 10
2023-02-27 16:17 ET
TransMedics Group reported for 2022 q4
SEC form 10
2023-02-27 00:00 ET
TransMedics Group reported for 2022 q4
SEC form 6
2023-02-24 16:31 ET
TransMedics Group published news for 2022 q4
SEC form 6
2023-02-22 16:16 ET
TransMedics Group published news for 2022 q4
SEC form 8
2023-02-22 00:00 ET
TransMedics Group reported for 2022 q4
SEC form 6
2023-02-02 17:49 ET
TransMedics Group published news for 2022 q4
SEC form 6
2022-11-04 16:31 ET
TransMedics Group published news for 2022 q3
SEC form 10
2022-11-04 16:16 ET
TransMedics Group reported for 2022 q3
SEC form 10
2022-11-04 00:00 ET
TransMedics Group reported for 2022 q3
SEC form 6
2022-11-03 16:16 ET
TransMedics Group published news for 2022 q3
SEC form 8
2022-11-03 00:00 ET
TransMedics Group reported for 2022 q3
SEC form 6
2022-08-08 08:52 ET
TransMedics Group published news for 2022 q2
SEC form 10
2022-08-03 16:07 ET
TransMedics Group reported for 2022 q2
SEC form 10
2022-08-03 00:00 ET
TransMedics Group reported for 2022 q2
SEC form 6
2022-08-01 16:15 ET
TransMedics Group published news for 2022 q2
SEC form 8
2022-08-01 00:00 ET
TransMedics Group reported for 2022 q2
SEC form 6
2022-07-29 16:16 ET
TransMedics Group published news for 2022 q2
SEC form 6
2022-06-02 16:30 ET
TransMedics Group published news for 2022 q1
SEC form 10
2022-05-05 16:16 ET
TransMedics Group reported for 2022 q1
SEC form 10
2022-05-05 00:00 ET
TransMedics Group reported for 2022 q1
SEC form 6
2022-05-03 16:15 ET
TransMedics Group published news for 2022 q1
SEC form 8
2022-05-03 00:00 ET
TransMedics Group reported for 2022 q1
SEC form 6
2022-04-20 16:02 ET
TransMedics Group published news for 2022 q1
SEC form 10
2022-03-01 16:16 ET
TransMedics Group published news for 2021 q4
SEC form 10
2022-03-01 00:00 ET
TransMedics Group published news for 2021 q4
SEC form 6
2022-02-23 16:16 ET
TransMedics Group published news for 2021 q4
SEC form 8
2022-02-23 00:00 ET
TransMedics Group published news for 2021 q4
SEC form 10
2021-11-09 17:00 ET
TransMedics Group published news for 2021 q3
SEC form 6
2021-11-09 16:16 ET
TransMedics Group published news for 2021 q3
SEC form 10
2021-11-09 00:00 ET
TransMedics Group published news for 2021 q3
SEC form 8
2021-11-09 00:00 ET
TransMedics Group published news for 2021 q3
SEC form 6
2021-09-29 07:15 ET
TransMedics Group published news for 2021 q2
SEC form 6
2021-09-07 07:39 ET
TransMedics Group published news for 2021 q2
SEC form 6
2021-08-09 07:26 ET
TransMedics Group published news for 2021 q2
SEC form 6
2021-08-06 17:03 ET
TransMedics Group published news for 2021 q2
SEC form 10
2021-08-06 16:16 ET
TransMedics Group published news for 2021 q2
SEC form 10
2021-08-06 00:00 ET
TransMedics Group published news for 2021 q2
SEC form 6
2021-08-05 16:28 ET
TransMedics Group published news for 2021 q2
SEC form 6
2021-07-15 06:07 ET
TransMedics Group published news for 2021 q2
SEC form 6
2021-05-28 16:05 ET
TransMedics Group published news for 2021 q1
SEC form 10
2021-05-07 06:01 ET
TransMedics Group published news for 2021 q1
SEC form 10
2021-05-07 00:00 ET
TransMedics Group published news for 2021 q1
SEC form 6
2021-05-04 16:15 ET
TransMedics Group published news for 2021 q1
SEC form 6
2021-04-16 16:10 ET
TransMedics Group published news for 2021 q1
SEC form 6
2021-04-07 06:07 ET
TransMedics Group published news for 2021 q1
SEC form 6
2021-03-24 18:45 ET
TransMedics Group published news for 2020 q4
SEC form 6
2021-03-24 16:31 ET
TransMedics Group published news for 2020 q4
SEC form 10
2021-03-11 16:19 ET
TransMedics Group published news for 2020 q4
SEC form 6
2021-03-02 16:15 ET
TransMedics Group published news for 2020 q4
SEC form 6
2021-01-05 17:51 ET
TransMedics Group published news for 2020 q4
SEC form 6
2020-12-23 16:12 ET
TransMedics Group published news for 2020 q3
SEC form 10
2020-11-06 16:07 ET
TransMedics Group published news for 2020 q3
SEC form 6
2020-11-04 16:08 ET
TransMedics Group published news for 2020 q3